MajorSecond-generation systemic triazole antifungal×HIV protease inhibitor / pharmacokinetic booster
Updated · Methodology
Mechanism
CYP3A4 and CYP3A5 metabolise isavuconazole (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA), and ritonavir is a strong CYP3A inhibitor (ritonavir SmPC, EMA). At the booster dose, 100 mg with lopinavir 400 mg twice daily, ritonavir increased isavuconazole exposure (area under the curve, AUC) by 96%, while isavuconazole reduced the AUC of lopinavir by 27% and of ritonavir by 31% (isavuconazole SmPC, EMA, and prescribing information, US Food and Drug Administration, FDA). High ritonavir doses have not been studied with isavuconazole (EMA). The European isavuconazole SmPC says that at high doses ritonavir may induce CYP3A4 and CYP3A5 and markedly lower isavuconazole levels (EMA). The US label gives the opposite reason for the contraindication: strong CYP3A4 inhibitors may markedly raise isavuconazole levels (FDA).
Symptoms
With high-dose ritonavir, isavuconazole levels may fall markedly (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). If isavuconazole levels rise instead, adverse reactions may increase. At three times the usual maintenance dose of isavuconazole, headache, dizziness, tingling, numbness in the mouth, sleepiness, poor attention, taste disturbance, dry mouth, diarrhoea, vomiting, flushing, anxiety, restlessness, palpitations, fast heart rate, sensitivity to light and joint pain were more frequent (isavuconazole SmPC, EMA, and prescribing information, US Food and Drug Administration, FDA). Isavuconazole lowers lopinavir and ritonavir levels, and the antiviral effect may weaken (EMA, FDA).
Management
Isavuconazole is contraindicated with high-dose ritonavir. The European isavuconazole SmPC gives different thresholds in two sections: 200 mg twice daily or more in the interactions section and more than 200 mg every 12 hours in the contraindications section. The US label gives 400 mg every 12 hours (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, and prescribing information, US Food and Drug Administration, FDA). As an antiretroviral in its own right, ritonavir is taken at 600 mg twice daily, and as the booster for tipranavir at 200 mg twice daily (ritonavir SmPC, EMA). Only the interactions section puts the 200 mg dose under the contraindication (EMA). With booster-dose ritonavir, such as 100 mg with lopinavir 400 mg twice daily, the documents do not prohibit the combination: they keep the isavuconazole dose unchanged but advise caution, because adverse reactions may increase (EMA, FDA). Do not change the lopinavir/ritonavir dose either, but watch closely for any loss of antiviral effect (EMA). When ritonavir boosts another protease inhibitor, also review the contraindications in that drug's own SmPC (ritonavir SmPC, EMA). For boosted darunavir with isavuconazole, the Spanish SmPC recommends caution and clinical monitoring (darunavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Test liver function at the start of and during isavuconazole treatment (FDA), and do not give ritonavir to patients with decompensated liver function (ritonavir SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Darunavir (Darunavir Aurovitas, nº registro 84835), sección 4.5 (2023)– AEMPS, CIMA, nº registro 84835, revisión 09/2023, secciones 4.3 y 4.5
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.5 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4, 4.5, 4.9 y 5.2
- FDA: CRESEMBA (isavuconazonium sulfate) prescribing information (2025)– FDA, DailyMed setid 8f7f73b8-586a-4df0-935f-fecd4696c16c (Astellas Pharma US), revisión 04/2025 (versión 21), secciones 4, 5.1, 5.5, 7, 10 y 12.3
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.3 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Ritonavir, Norvir (EU/1/96/016), sección 4.2 (2026)– EMA, Norvir 100 mg comprimidos recubiertos con película (AbbVie Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 96016005, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.2 y 4.3